knowledge -WSS

knowledge

author：hotspot 2025-09-03 03:38:41 - browse：177

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： As pharma fights Medicare drug negotiation, hospitals, docs silent

focus

WSS

What do new weight loss drugs mean for bariatric surgery?

Apellis safety probe of eye disease drug centers on injection needle

2024 GOP presidential candidates spar over abortion in debate

Study finds new variant for Parkinson’s in African populations

6 solutions to address cancer drug shortages and others

Winners, losers from Medicare’s list of drugs subject to price talks

Wikipedia

knowledge

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Psilocybin's anti

How to save PrEP access — and even expand it

Congress extends some pandemic preparedness programs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Diversity in medical illustrations gets boost from Chidiebere Ibe

As demand for Covid shots wanes, Moderna seeks its next success

2024 GOP presidential candidates spar over abortion in debate

How one medical school became remarkably diverse

Congress extends some pandemic preparedness programs

explore

Feds fine Medicare Advantage plans for overcharging members

Departing Stanford president retracts two papers

Flu, Covid vaccination rates decline, new survey data show

Stop Congress from blocking public access to science

Complete sequence of Y chromosome published for first time

WHO recommends second malaria vaccine

focus

Wikipedia

Wikipedia

explore